论文部分内容阅读
目的探讨晚期非小细胞肺癌中Stathmin和Survivin的表达与多西紫杉醇化疗疗效的关系。方法回顾性分析72例接受多西紫杉醇化疗的晚期非小细胞肺癌患者的临床病理资料。免疫组织化学法检测肿瘤标本Stathmin和Survivin蛋白的表达,并对疗效、不良反应进行分析。结果 Stathmin阳性表达率为65.27%(47/72),Survivin阳性表达率为76.38%(55/72)。化疗有效率(CR+PR)为51.38%,Stathmin(?)的患者有效率(33.33%)显著低于Stathmin(?)患者(66.67%)(P<0.05)。Survivin(+)组的有效率(38.18%)显著低于Survivin(?)组的76.47%(P<0.05)。联合检测显示:Stathmin(+)且Survivin(+)组有效率为28.94%,中位疾病无进展时间为3.7个月,1年生存率为29.9%,Stathmin(?)且Survivin(?)组有效率为87.50%,中位疾病无进展时间为7.1个月,1年生存率为62.5%,差异均有显著性(P<0.05)。最常见的不良反应为骨髓抑制、消化道反应和脱发。结论联合检测Stathmin和Survivin的表达可作为多西紫杉醇化疗方案治疗晚期非小细胞肺癌的疗效预测指标之一。
Objective To investigate the relationship between Stathmin and Survivin expression and the efficacy of docetaxel chemotherapy in advanced non-small cell lung cancer. Methods The clinical data of 72 patients with advanced non-small cell lung cancer receiving docetaxel chemotherapy were retrospectively analyzed. Immunohistochemistry was used to detect the expression of Stathmin and Survivin protein in tumor samples. The curative effect and adverse reaction were analyzed. Results The positive rate of Stathmin was 65.27% (47/72) and the positive rate of Survivin was 76.38% (55/72). The effective rate of chemotherapy (CR + PR) was 51.38%, and the effective rate of Stathmin (?) Was significantly lower than that of Stathmin (?) (33.33% vs 66.67%, P <0.05). The effective rate (38.18%) in Survivin (+) group was significantly lower than that in Survivin (?) Group 76.47% (P <0.05). The combined test showed that the effective rate of Stathmin (+) and Survivin (+) group was 28.94%, the median progression-free time was 3.7 months, the 1-year survival rate was 29.9%, Stathmin (?) And Survivin The effective rate was 87.50%. The median progression-free time was 7.1 months and the 1-year survival rate was 62.5%. The difference was significant (P <0.05). The most common adverse reactions are myelosuppression, gastrointestinal reactions and hair loss. Conclusions Combined detection of Stathmin and Survivin expression may be one of the predictors of efficacy of docetaxel chemotherapy in the treatment of advanced non-small cell lung cancer.